97- Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel
PL. Modifi ed disease activity scores that include twenty-eight-joint counts. Development and
validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis
Rheum. 1995;38(1):44–8. - Aletaha D, Smolen J. The simplifi ed disease activity index (SDAI) and the clinical disease
activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin
Exp Rheumatol. 2005;23(5 Suppl 39):S100–8. - Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheu-
matoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical
trials and clinical care. Rheum Dis Clin North Am. 2009;35(4):773–8. viii. - Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, obser-
vational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol.
2005;32(12):2410–5. - Fleischer Jr AB, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR, et al. Disease
severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate
with self-administered psoriasis area severity index scores. J Investig Dermatol.
1996;107(1):26–9. - Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of
response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis
of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann
Rheum Dis. 2006;65(10):1373–8. - Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study
of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol.
1993;20(4):657–60. - Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG
index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus
erythematosus. Q J Med. 1993;86(7):447–58. - Swaak AJ, van den Brink HG, Smeenk RJ, Manger K, Kalden JR, Tosi S, et al. Systemic
lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years:
second evaluation. Lupus. 2001;10(1):51–8. - Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the
routine clinic setting. J Rheumatol. 1992;19(1):53–9. - Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the
ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythe-
matosus. Lupus. 2000;9(6):445–50. - Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity
in systemic lupus erythematosus: report of the Consensus Study Group of the European
Workshop for Rheumatology Research. III. Development of a computerised clinical chart
and its application to the comparison of different indices of disease activity. The European
Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol.
1992;10(5):549–54. - Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reli-
ability of the systemic lupus international collaborating clinics/American College of
Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum.
1997;40(5):809–13. - Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al.
Validation of a systemic lupus activity questionnaire (SLAQ) for population studies. Lupus.
2003;12(4):280–6. - Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to
defi ning disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease
activity index. J Rheumatol. 1994;21(12):2286–91.
3 PROMs (MDHAQ/RAPID3) and Physician RheuMetric Measures